Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis

References

• Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007 21;370(9583):272–284. doi: 10.1016/S0140-6736(07)61129-5
   PubMed Web of Science ®Google Scholar
• Wu JJ. Contemporary management of moderate to severe plaque psoriasis. Am J Manag Care. 2017;23(21 Suppl):S403–S416.
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498. doi: 10.1111/jdv.16915
   PubMed Web of Science ®Google Scholar
• Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015;75(3):329–338. doi: 10.1007/s40265-015-0359-0
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luger T, Thaçi D, et al. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 2017;177(4):1033–1042. doi: 10.1111/bjd.15706
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, Atzori L, et al. Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study. Expert Opin Biol Ther. 2022;22(4):547–554. doi: 10.1080/14712598.2022.2029841
   PubMed Web of Science ®Google Scholar
• Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017;77(4):667–674. doi: 10.1016/j.jaad.2017.05.033
   PubMed Web of Science ®Google Scholar
• AlMutairi N, Eassa BI. A randomized controlled ixekizumab Vs secukinumab trial to study the Impact on sexual activity in adult patients with genital psoriasis. Expert Opin Biol Ther. 2021;21(2):297–298. doi: 10.1080/14712598.2021.1843629
   PubMed Web of Science ®Google Scholar
• Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2021;184(3):425–436. doi: 10.1111/bjd.19262
   PubMed Web of Science ®Google Scholar
• Tsai YC, Tsai TF. Switching biologics in psoriasis - practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13(5):493–503. doi: 10.1080/17512433.2020.1767590
   PubMed Web of Science ®Google Scholar
• Brownstone ND, Hong J, Mosca M, et al. Biologic treatments of psoriasis: an update for the clinician. Biologics. 2021;15:39–51. doi: 10.2147/BTT.S252578
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi: 10.1016/j.jaad.2018.11.057
   PubMed Web of Science ®Google Scholar
• Shin JO, Shin BS, Bae KN, et al. Review of the reasons for and effectiveness of switching biologics for psoriasis treatment in Korea. Indian J Dermatol Venereol Leprol. 2023;89(6):928. doi: 10.25259/IJDVL_308_2022
   PubMed Web of Science ®Google Scholar
• US Food and drug administration. FDA approves new psoriasis drug cosentyx. [press release]. 2015 Jan 21 [cited 2015 Jun 10]. Available from: wwwfdagov/NewsEvents/Newsroom/PressAnnouncements/ucm430969htm
   Google Scholar
• Torres T, Puig L, Vender R, et al. Drug survival of interleukin (IL)‑17 and IL‑23 inhibitors for the treatment of psoriasis: a retrospective multi‑country, multicentric cohort study. Am J Clin Dermatol. 2022 Nov;23(6):891–904. doi: 10.1007/s40257-022-00722-y
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Malagoli P, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis). Front Immunol. 2024;14:1341708. doi: 10.3389/fimmu.2023.1341708
   PubMed Web of Science ®Google Scholar
• Nguyen HT, Pham NTU, Tran TNA, et al. Long-term effectiveness and drug survival of Secukinumab in Vietnamese patients with psoriasis: results from a retrospective ENHANCE study. Dermatol Ther (Heidelb). 2023;13(2):465–476. doi: 10.1007/s13555-022-00867-y
   PubMed Web of Science ®Google Scholar
• Jung SW, Lim SH, Jeon JJ, et al. Comparison of the efficacy and safety of biologics (secukinumab, Ustekinumab, and Guselkumab) for the treatment of moderate-to-severe psoriasis: real-world data from a Single Korean Center. Biomedicines. 2022;10(5):1058. doi: 10.3390/biomedicines10051058
   PubMed Web of Science ®Google Scholar
• Gambardella A, Licata G, Sohrt A. Dose adjustment of biologic treatments for moderate-to-severe plaque psoriasis in the real world: a systematic review. Dermatol Ther (Heidelb). 2021;11(4):1141–1156. doi: 10.1007/s13555-021-00559-z
   PubMed Web of Science ®Google Scholar
• Schwensen JF, Clemmensen A, Sand C, et al. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: a retrospective multicenter study. Dermatol Ther. 2017;30(6):e12550. doi: 10.1111/dth.12550
   Web of Science ®Google Scholar
• Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–519. doi: 10.1111/bjd.16102
   PubMed Web of Science ®Google Scholar
• Carvalho AL, Hedrich CM. The Molecular pathophysiology of psoriatic arthritis-the complex interplay between genetic predisposition, epigenetics factors, and the microbiome. Front Mol Biosci. 2021;8:662047. doi: 10.3389/fmolb.2021.662047
   PubMed Web of Science ®Google Scholar
• Ortolan A, Lorenzin M, Leo G, et al. Secukinumab drug survival in psoriasis and psoriatic arthritis patients: a 24-month real-life study. Dermatology. 2022;238(5):897–903. doi: 10.1159/000522008
   PubMed Web of Science ®Google Scholar
• Daudén E, de Lima GPG, Armesto S, et al. Multicenter retrospective study of secukinumab drug survival in psoriasis patients in a daily practice setting: a long-term experience in Spain. Dermatol Ther (Heidelb). 2021;11(6):2207–2215. doi: 10.1007/s13555-021-00606-9
   PubMed Web of Science ®Google Scholar
• Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008;58(3):443–446. doi: 10.1016/j.jaad.2007.11.011
   PubMed Web of Science ®Google Scholar
• Pirro F, Caldarola G, Chiricozzi A, et al. Impact of Body Mass Index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41(10):917–925. doi: 10.1007/s40261-021-01080-z
   PubMed Web of Science ®Google Scholar
• Augustin M, Reich K, Yamauchi P, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022;186(6):942–954. doi: 10.1111/bjd.20971
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Wu JJ, Griffiths CEM, et al. Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials. J Dermatolog Treat. 2022;33(3):1482–1490. doi: 10.1080/09546634.2020.1832187
   PubMed Web of Science ®Google Scholar
• Alabas OA, Mason KJ, Yiu ZZN, et al. BADBIR and BSTOP study group. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2024;190(5):689–700. doi: 10.1093/bjd/ljad481
   PubMed Web of Science ®Google Scholar
• Viola R, Mastorino L, Megna M, et al. Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort. Int J Dermatol. 2024 Mar;63(3):351–358. doi: 10.1111/ijd.17005
   PubMed Web of Science ®Google Scholar
• Schots L, Soenen R, Blanquart B, et al. Blocking interleukin-17 in psoriasis: Real-world experience from the PsoPlus cohort. J Eur Acad Dermatol Venereol. 2023 Apr;37(4):698–710. doi: 10.1111/jdv.18827
   PubMed Web of Science ®Google Scholar
• Seneschal J, Lacour JP, Bewley A, et al. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). J Eur Acad Dermatol Venereol. 2020;34(11):2566–2573. doi: 10.1111/jdv.16568
   PubMed Web of Science ®Google Scholar
• Bagel J, Butler B, Nelson E, et al. A retrospective review of patients’ response to biologic therapy for psoriasis. J Drugs Dermatol. 2021;20(4):442–449. doi: 10.36849/JDD.5823
   PubMed Web of Science ®Google Scholar
• Hampton P, Halliday A, Aassi M, et al. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: post hoc analysis of six randomised trials. J Eur Acad Dermatol Venereol. 2021;35(4):928–937. doi: 10.1111/jdv.16982
   PubMed Web of Science ®Google Scholar
• Strober B, Patil D, McLean RR, et al. Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting. J Dermatolog Treat. 2022;33(8):3178–3187. doi: 10.1080/09546634.2022.2116266
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Silvaggio D, et al. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther. 2020;20(2):173–182. doi: 10.1080/14712598.2020.1708897
   PubMed Web of Science ®Google Scholar
• Pinter A, Gerdes S, Papavassilis C, et al. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. J Dermatolog Treat. 2020;31(8):769–775. doi: 10.1080/09546634.2019.1626973
   PubMed Web of Science ®Google Scholar
• Rompoti N, Sidiropoulou P, Panagakis P, et al. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. J Eur Acad Dermatol Venereol. 2020;34(6):1240–1247. doi: 10.1111/jdv.16202
   PubMed Web of Science ®Google Scholar
• Tada Y, Morita A, Yamanaka K, et al. Real-world retention rates and effectiveness of secukinumab in psoriasis: results from a multicenter cohort study (RAILWAY). J Dermatol. 2023;50(11):1415–1426. doi: 10.1111/1346-8138.16926
   PubMed Web of Science ®Google Scholar